Biogen ANZ News and Activities

Biogen ANZ is owned by Biogen.

Biogen is one of the...

• Forbes Global 2000 (#845);
• Fortune 500 (#401);
• Russell 3000;
• S&P 500;
• TOB Iconic 10,000.

Biogen is a company listed under the stock ticker BIIB (US).

Biogen has a direct presence in 9 countries.

Biogen has 9 subsidiaries including Biogen ANZ, Biogen BeLux and Biogen Canada.

They are in:

• Biotechnology90%
• Medical Equipment10%

Acquisition, funding and merger involving Biogen.

• Biogen has announced the acquisition of Apellis Pharmaceuticals  (posted on March 31 2026).
• Biogen has announced the acquisition of Alcyone Therapeutics  (posted on September 24 2025).
• Biogen has announced the acquisition of HI-Bio  (posted on July 3 2024).

View the org chart displaying its 2 main executives

Most searched biographies at Biogen ANZ

• David Henderson, Managing Director
• Krishna Nair, Finance Director

Popular executive movements at Biogen

• Maria Freire, who was Director, is promoted to Chairman of the Board  (posted on February 13 2026).
• Caroline Dorsa, Chairman of the Board, will leave the company on Jun. 9, 2026  (posted on February 13 2026).

Create your alert
to follow the executive moves at Biogen ANZ.

Biogen has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Biogen ANZ

• EISAI PRESENTS NEW FINDINGS ON LECANEMAB’S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022 | Biogen
• The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus | Biogen
• FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS | Biogen
• Biogen to Report Second Quarter 2022 Financial Results July 20, 2022 | Biogen
• The U.S. FDA Accepts and Grants Priority Review for EISAI’s Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway | Biogen
• Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform | Biogen
• European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate) | Biogen
• New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen) | Biogen
• The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities | Biogen
• Biogen Withdrawal from the Jefferies Healthcare Conference | Biogen
• View more press releases Close

Social media about Biogen ANZ

• Biogen ANZ on Wikipedia, Google News & Yahoo Finance
• Biogen ANZ on LinkedIn, X (Twitter) & YouTube